Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828219 | 0.87 | GABRP (0.42) | FOLH1PRMT1EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL19360008 | 0.86 | PRMT1 (0.49) | FOLH1PRMT1EPHX1ADRA1ASMN1; SMN2 | |
| SCHEMBL15275337 | 0.85 | EPHX1 (0.49) | FOLH1PRMT1EPHX1ADRA1ASMN1; SMN2 | |
| SCHEMBL19265779 | 0.84 | FOLH1 (0.61) | FOLH1MEN1ALDH1A1PLGLMNA | |
| SCHEMBL12118207 | 0.82 | PRMT1 (0.45) | FOLH1PRMT1EPHX1ADRA1ASMN1; SMN2 | |
| SCHEMBL21321739 | 0.82 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL2742760 | 0.82 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL19788056 | 0.82 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL2742756 | 0.81 | FOLH1 (0.42) | FOLH1PRMT1EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL19788055 | 0.81 | FOLH1 (0.42) | FOLH1PRMT1EPHX1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367481-A1 | CANCER CELL TARGETING USING NANOPARTICLES | PFIZER INC. | 2016-12-22 | — | — | US | disclosed |
| US-8734846-B2 | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles | BIND BIOSCIENCES, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | BIND BIOSCIENCES, INC (US) | 2013-05-09 | — | — | US | disclosed |
| US-8293276-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8273363-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8236330-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885PRMT1 3790/4885PAOX 2459/4885 |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885PRMT1 2310/4885PAOX 3698/4885 |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | GNE, PAM, EPHA2 | FOLH1 727/4885PRMT1 3811/4885PAOX 1413/4885 |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885PRMT1 2310/4885PAOX 3698/4885 |
| US-20160367481-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | FOLH1 279/4885PRMT1 2310/4885PAOX 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.